BIOLIFE4D Modifies its Regulation A+ (Mini-IPO) Offering Following Significant Scientific Achievement

Company surpasses $3M in accepted investments 

CHICAGO – September 16, 2019 – BIOLIFE4D, a biotech pioneer leveraging advances in tissue engineering to 3D print human organs viable for transplant, announced it has modified its Regulation A+ (Mini-IPO) offering following a successful September re-launch. BIOLIFE4D has raised more than $3M in equity crowdfunding investments since February of 2018. 

BIOLIFE4D’s modified Regulation A+ offering will allow the company to sell up to 3,965,493 shares of its securities to the public. BIOLIFE4D is now offering shares at $13.50 USD per share with a minimum investment of 80 shares for $1,080 USD. The offering will be conducted on a best efforts basis through our website, https://biolife4d.com/investing-in-biolife/, where a link to the Offering Circular relating to the offering is posted.

BIOLIFE4D has chosen to raise its share price after reaching a significant scientific milestone of 3D bioprinting a mini-heart, which has been featured in high profile publications like ForbesDigital Trends LiveNBC ChicagoEngadget, and more. BIOLIFE4D believes it is advancing rapidly, and is well ahead of schedule in its scientific process as it seeks to 3D bioprint a viable human heart for transplant.

To learn more about BIOLIFE4D and to express interest in investing please visit https://biolife4d.com/investing-in-biolife/.

To see how BIOLIFE4D’s process starts with a patient’s own cells and ends with a functional human heart ready for transplant, please watch this video.

About BIOLIFE4D

BIOLIFE4D is a pioneering biotech company laser focused on leveraging advances in life sciences and tissue engineering to 3D bioprint a viable human heart suitable for transplant – lifesaving technology that gives patients the gift of time. With BIOLIFE4D, a patient-specific, fully functioning heart will be created through 3D bioprinting using the patient’s own cells – eliminating the well-known challenges of organ rejection and long donor waiting lists that plague existing organ transplant methods. Financed through equity crowdfunding, BIOLIFE4D is driving a movement to transform the treatment of heart disease, the leading cause of death among both men and women globally. Learn more and invest at biolife4d.com. Connect with us on social media on Twitter (@BIOLIFE4D), FacebookLinkedIn, and Instagram.

###

Forward Looking Statements We caution you that, whether or not expressly stated, certain statements made in this news release that reflect management’s expectations regarding future events and economic performance are forward-looking in nature and, accordingly, are subject to risks and uncertainties. All statements other than statements of historical facts included in this press release are forward-looking statements. In some cases, forward-looking statements can be identified by words such as “believe,” “expect,” “anticipate,” “plan,” “potential,” “continue” or similar expressions. Such forward-looking statements include risks and uncertainties, and there are important factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. Investors should not place any undue reliance on forward-looking statements since they involve known and unknown, uncertainties and other factors which are, in some cases, beyond the Company’s control which could, and likely will, materially affect actual results, levels of activity, performance or achievements. 


Build a Heart. Save a life.

Scroll Up